Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 08, 2023

Encorafenib Plus Binimetinib and Cetuximab for Previously Untreated BRAF V600E–Mutant Metastatic Colorectal Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer
J. Clin. Oncol 2023 Feb 10;[EPub Ahead of Print], E Van Cutsem, J Taieb, R Yaeger, T Yoshino, A Grothey, E Maiello, E Elez, J Dekervel, P Ross, A Ruiz-Casado, J Graham, T Kato, JC Ruffinelli, T André, E Carrière Roussel, I Klauck, M Groc, JC Vedovato, J Tabernero

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading